Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight ...